US Patent No: 7,718,776

Number of patents in Portfolio can not be more than 2000

Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors

1 Status Updates

Stats

ALSO PUBLISHED AS: 20040023313
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
MEDAREX, INC.PRINCETON, NJ137

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Boyle, William J Fallbrook, CA 115 3006
Elliott, Robin L Newbury Park, CA 7 20
Huang, Haichun Fremont, CA 66 106
Martin, Frank San Clemente, CA 29 145
Medlock, Eugene Westlake Village, CA 22 66
Sullivan, John J 270 Morgan St., South Hadley, MA 01075 11 53

Cited Art

Patent Info (Count) # Cites Year
 
IMMUNEX CORPORATION (24)
5,457,035 Cytokine which is a ligand for OX40 43 1993
5,961,974 Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same 25 1994
5,763,223 DNA encoding a cytokine that induces apoptosis 65 1996
6,017,729 Receptor activator of NF-.kappa.B 47 1997
6,242,213 Isolated DNA molecules encoding RANK-L 37 1997
6,271,349 Receptor activator of NF-.kappa.B 24 1998
6,528,482 Receptor activator of NF-.kappa.B 22 1999
6,419,929 Recombinant RANK-L polypeptide 25 2000
6,479,635 Receptor activator of NF-.kappa.B 13 2000
6,838,262 Isolated DNA molecule encoding rank ligand 12 2000
6,740,522 Antibodies against ligand for receptor activator of NF-kB 23 2001
6,562,948 Receptor activator of NF-.kappa.B 18 2001
6,537,763 Receptor activator of NF-.kappa.B 23 2001
6,649,164 Method for enhancing the functional capacity of dendritic cells 15 2001
6,884,598 Screening assays for agonists and antagonists of receptor activator of NF-.kappa.B 5 2001
2003/0017,151 Therapeutic use of rank antagonists 9 2002
2003/0021,785 Use of rank antagonists to treat cancer 8 2002
7,262,274 Kits containing rank polypeptides 10 2003
7,411,050 Monoclonal blocking antibody to human RANKL 9 2004
7,572,594 Screening assays for agonists or antagonists or receptor activator of NF-κB 3 2005
2005/0196,801 Screening assays for agonists or antagonists or receptor activator of NF-kappaB 3 2005
2008/0009,014 Receptor activator of NF-kappaB 6 2007
2009/0004,196 METHOD OF INHIBITING OSTEOCLAST ACTIVITY 5 2008
2009/0017,033 Methods for interfering with RANKL signaling 4 2008
 
AMGEN INC. (15)
6,369,027 Osteoprotegerin 24 1996
6,284,485 Nucleic acids encoding osteoprotegerin 24 1997
6,284,728 Osteoprotegerin 19 1997
6,288,032 Osteoprotegerin 21 1997
5,843,678 Osteoprotegerin binding proteins 55 1997
6,087,555 Mice lacking expression of osteoprotegerin 56 1997
6,015,938 Osteoprotegerin 42 1997
6,284,740 Osteoprotegerin 20 1997
6,316,408 Methods of use for osetoprotegerin binding protein receptors 37 1998
7,097,834 Osteoprotegerin binding proteins 27 1998
2003/0103,978 Selective binding agents of osteoprotegerin binding protein 22 2001
7,084,257 Fully human antibody Fab fragments with human interferon-gamma neutralizing activity 27 2001
7,364,736 Antibodies to OPGL 7 2002
2005/0003,400 Osteoprotegerin binding proteins and receptors 6 2004
2006/0246,064 Osteoprotegerin binding proteins 6 2006
 
GENPHARM INTERNATIONAL, INC. (10)
5,569,825 Transgenic non-human animals capable of producing heterologous antibodies of various isotypes 306 1991
5,633,425 Transgenic non-human animals capable of producing heterologous antibodies 280 1992
5,789,650 Transgenic non-human animals for producing heterologous antibodies 125 1992
5,545,806 Ransgenic non-human animals for producing heterologous antibodies 363 1992
5,661,016 Transgenic non-human animals capable of producing heterologous antibodies of various isotypes 263 1993
5,814,318 Transgenic non-human animals for producing heterologous antibodies 129 1993
5,877,397 Transgenic non-human animals capable of producing heterologous antibodies of various isotypes 170 1994
5,625,126 Transgenic non-human animals for producing heterologous antibodies 281 1994
5,770,429 Transgenic non-human animals capable of producing heterologous antibodies 142 1995
5,874,299 Transgenic non-human animals capable of producing heterologous antibodies 62 1997
 
DAIICHI SANKYO COMPANY, LIMITED (5)
7,527,790 Methods of reducing bone absorption comprising administering an antibody that binds OBM 6 2002
2003/0176,647 Antibodies to OCIF-binding molecules 12 2002
7,192,718 Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof 6 2003
7,449,185 Antibodies to OCIF-binding molecules 6 2004
2005/0208,580 Novel protein and method for producing the protein 6 2005
 
PROTEIN DESIGN LABS, INC. (5)
5,530,101 Humanized immunoglobulins 602 1990
5,585,089 Humanized immunoglobulins 611 1995
5,693,761 Polynucleotides encoding improved humanized immunoglobulins 263 1995
5,693,762 Humanized immunoglobulins 473 1995
6,180,370 Humanized immunoglobulins and methods of making the same 299 1995
 
GENETICS INSTITUTE, LLC (3)
4,740,461 Vectors and methods for transformation of eucaryotic cells 127 1983
4,912,040 Eucaryotic expression system 55 1987
4,959,455 Primate hematopoietic growth factors IL-3 and pharmaceutical compositions 103 1987
 
HUMAN GENOME SCIENCES, INC. (3)
2003/0166,097 Human tumor necrosis factor receptor 14 2002
2002/0150,989 Human tumor necrosis factor receptor 14 2002
2003/0100,069 Human tumor necrosis factor receptor-like protein 8 13 2002
 
NEUROTECH S.A. (3)
4,892,538 In vivo delivery of neurotransmitters by implanted, encapsulated cells 253 1987
5,011,472 Implantable delivery system for biological factors 150 1988
5,106,627 Neurological therapy devices 141 1990
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (2)
4,474,893 Recombinant monoclonal antibodies 216 1981
5,985,832 Compositions and methods of use for osteoclast inhibitor factors 21 1998
 
CELTRIX PHARMACEUTICALS, INC. (2)
5,118,667 Bone growth factors and inhibitors of bone resorption for promoting bone formation 129 1991
5,393,739 Use of bone morphogenetic protein in synergistic combination with TGF-.beta. for bone repair 63 1993
 
ENZON, INC. (2)
4,946,778 Single polypeptide chain binding molecules 932 1989
5,260,203 Single polypeptide chain binding molecules 108 1990
 
GENENTECH, INC. (2)
4,816,567 Recombinant immunoglobin preparations 1317 1983
6,046,048 Apo-2 ligand 16 1997
 
MERCK SHARP & DOHME CORP. (2)
6,242,586 Mammalian cell surface antigens: related reagents 30 1997
6,525,180 Antibodies to mammalian T cell surface antigen 23 2000
 
ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (1)
5,843,901 LHRH antagonist peptides 28 1995
 
AMGEN A CORP. OF CALIFORNIA (1)
4,710,473 DNA plasmids 66 1984
 
BTG INTERNATIONAL LIMITED (1)
6,569,430 Antibodies to the antigen Campath-1 15 1995
 
CHIRON CORPORATION (1)
4,959,314 Cysteine-depleted muteins of biologically active proteins 182 1985
 
DEMAND INSIGHTS LLC (1)
7,120,598 Method for managing an investment portfolio 10 2003
 
EASTMAN KODAK COMPANY (1)
5,234,784 Method of making a projection viewable transparency comprising an electrostatographic toner image 34 1992
 
FINCH UNIVERSITY OF HEALTH SCIENCES/THE CHICAGO MEDICAL SCHOOL (1)
5,641,747 Treatment of osteopetrotic diseases 13 1994
 
GENSCI REGENERATION SCIENCES INC. (1)
5,578,569 Method of increasing bone growth 39 1994
 
HILTI AKTIENGESELLSCHAFT (1)
6,851,898 Dust removal unit for a hand tool device 22 2002
 
IMMUNEX CORPORATION BY EDWARD V. FRITZKY (1)
5,447,851 DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells 138 1992
 
IMMUNOMEDICS, INC. (1)
4,699,880 Method of producing monoclonal anti-idiotype antibody 65 1984
 
INEX PHARMACEUTICALS CORPORATION (1)
5,151,510 Method of synethesizing sulfurized oligonucleotide analogs 74 1990
 
KOITO MANUFACTURING CO., LTD. (1)
5,618,098 Headlamp for vehicle 11 1995
 
LSI LOGIC CORPORATION (1)
5,625,825 Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network 54 1993
 
MEDICAL RESEARCH COUNCIL (1)
5,545,807 Production of antibodies from transgenic animals 280 1994
 
MEDICAL RESEARCH COUNCIL OF UNITED KINGDOM (1)
6,248,516 Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors 32 1995
 
MERCK & CO., INC. (1)
5,658,756 CDNA encoding a novel human protein tyrosine phosphatase 24 1994
 
OSTEOSA LIQUIDATION TRUST (1)
5,599,708 Osteoclast growth regulating factors and antibodies 21 1994
 
PHARMEXA A/S (1)
6,645,500 Method for down-regulating osteoprotegerin ligand activity 13 1999
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4,710,457 Monoclonal antibody for human hematopoietic glycoproteins and method 19 1983
 
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (1)
4,399,216 Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials 391 1980
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (1)
5,585,479 Antisense oligonucleotides directed against human ELAM-I RNA 238 1993
 
UNIVERSITEIT ANTWERPEN (1)
5,981,220 Epidermal differentiation factor 6 1997
 
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (1)
6,410,516 Nuclear factors associated with transcriptional regulation 58 1995
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (4)
2003/0104,485 ANTIBODIES SPECIFIC FOR OSTEOPROTEGERIN BINDING PROTEINS AND METHOD OF USE 17 1998
2003/0100,488 OSTEOPROTEGERIN BINDING PROTEINS 16 1998
2002/0127,637 Human tumor necrosis factor receptor-like protein 8 15 2001
2007/0009,520 Antibodies to OCIF-binding molecules 6 2006

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
AMGEN INC. (2)
8,058,418 Polynucleotides encoding heavy and light chains of antibodies to OPGL 2 2007
8,409,578 Methods for treating bone loss with antibodies to OPGL 0 2011
 
BIOGEN IDEC MA INC. (2)
8,128,926 Sp35 antibodies and uses thereof 1 2009
8,425,910 Composition comprising antibodies to LINGO or fragments thereof 0 2011
 
C. VAN DER LELY N.V. (1)
4,679,384 Mowing machine 6 1984
 
IMMUNEX CORPORATION (1)
8,333,963 Method of inhibiting osteoclast activity 0 2010

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Nov 18, 2013
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 18, 2017
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 18, 2021
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00